CD274 and neoplasm: Nevertheless, the combination blockade of IDO1 and PD‐1/PD‐L1 might be more appropriate for inflamed tumors, given that the driving factor for IDO1 expression in NSCLC patients is likely inflammation rather than the tumor itself.108